PHP
ERAS icon

Parkman Healthcare Partners’s Erasca ERAS Stock Holding History

Parkman Healthcare Partners’s Portfolio ERAS Stock Details ERAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.58M Buy
+406,702
New +$4.81M 0.68% 48

Other funds holding ERAS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Parkman Healthcare Partners's ERAS Position: Q1 2026 in Review

Parkman Healthcare Partners opened a new position in Erasca (ERAS) in Q1 2026: 406,702 shares worth $6.58M. The stake represents 0.68% of the portfolio and ranks #48 among its holdings.

225 funds tracked by Wall St. Rank hold ERAS as of Q1 2026.

  • Parkman Healthcare Partners held 406,702 shares of Erasca worth $6.58M as of Q1 2026.
  • Erasca was a new Parkman Healthcare Partners position in Q1 2026.
  • Erasca made up 0.68% of Parkman Healthcare Partners's portfolio in Q1 2026, its #48 holding.
  • 225 funds tracked by Wall St. Rank held Erasca as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.